Mabpharm Limited, a biopharmaceutical company, focuses on the research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in China. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has Mabpharm's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2181 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 2181's weekly volatility has decreased from 11% to 3% over the past year.
7 Day Return
1 Year Return
Return vs Industry: 2181 underperformed the Hong Kong Biotechs industry which returned 24.3% over the past year.
Return vs Market: 2181 underperformed the Hong Kong Market which returned 11.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Mabpharm's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StThe Mabpharm (HKG:2181) Share Price Is Up 12% And Shareholders Are Holding On
2 months ago | Simply Wall StCompanies Like Mabpharm (HKG:2181) Are In A Position To Invest In Growth
3 months ago | Simply Wall StIf You Had Bought Mabpharm (HKG:2181) Shares A Year Ago You'd Have Earned11% Returns
Is Mabpharm undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 2181's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 2181's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 2181 is unprofitable, so we can't compare its PE Ratio to the XA Biotechs industry average.
PE vs Market: 2181 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2181's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2181 is good value based on its PB Ratio (4x) compared to the HK Biotechs industry average (4.2x).
How is Mabpharm forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2181's forecast earnings growth is above the savings rate (1.6%).
Earnings vs Market: Insufficient data to determine if 2181's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2181's revenue (59.9% per year) is forecast to grow faster than the Hong Kong market (13.7% per year).
High Growth Revenue: 2181's revenue (59.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2181 is forecast to be unprofitable in 3 years.
How has Mabpharm performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 2181 is currently unprofitable.
Growing Profit Margin: 2181 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2181's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2181's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2181 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.2%).
Return on Equity
High ROE: 2181 has a negative Return on Equity (-14.01%), as it is currently unprofitable.
How is Mabpharm's financial position?
Financial Position Analysis
Short Term Liabilities: 2181's short term assets (CN¥776.6M) exceed its short term liabilities (CN¥273.4M).
Long Term Liabilities: 2181's short term assets (CN¥776.6M) exceed its long term liabilities (CN¥37.5M).
Debt to Equity History and Analysis
Debt Level: 2181's debt to equity ratio (0.05%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 2181's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2181 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 2181 has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 49.5% each year.
What is Mabpharm current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2181's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2181's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2181's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2181's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2181's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Mabpharm has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Mabpharm Limited's company bio, employee growth, exchange listings and data sources
- Name: Mabpharm Limited
- Ticker: 2181
- Exchange: SEHK
- Founded: 2018
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$4.701b
- Shares outstanding: 4.12b
- Website: https://www.mabpharm.cn
Number of Employees
- Mabpharm Limited
- Block G79
- Lujia Road East
- Zhejiang Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|2181||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||May 2019|
Mabpharm Limited, a biopharmaceutical company, focuses on the research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in China. Its products under the Phase ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/30 10:29|
|End of Day Share Price||2020/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.